Related Experiment Video
Updated: Jul 22, 2026
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
Delivery of adenoviral vectors to the prostate for gene therapy
1Department of Urology, University of Tennessee at Memphis 38163, USA. ylu@utmem1.utmem.edu
Abstract:
Prostate cancer has become the most frequently occurring cancer and the second leading cause of cancer deaths in men. One novel approach to combat prostate cancer is gene therapy. A replication-deficient recombinant adenoviral vector (AdRSVlacZ) expressing bacterial beta-galactosidase (beta-gal) (lacZ) under the control of the Rous sarcoma virus promoter was used to determine which delivery route was best for the transduction of adenoviral vectors to the prostate. Using a canine model, adenoviral vectors were administered by intravenous, intra-arterial, and intraprostatic (i.p.) injections. After injections, the expression of the lacZ gene was measured in canine prostates as well as in various other organs to determine the distribution of the disseminated adenoviral vector by (a) the percentage of cells expressing lacZ in situ (5-bromo-4-chloro-3-indolyl beta-D-galactoside staining), (b) beta-gal enzymatic activity (colorimetric beta-gal assay), and (c) polymerase chain reaction of genomic DNA using primers specific for the adenoviral genome. An i.p. injection of the adenoviral vector resulted in a greater transduction rate and expression level of lacZ in the prostate than either intravenous or intra-arterial (inferior vesical/prostatic artery) injections. Thus, an i.p. (or intratumoral) injection seems to be the best route to treat local regional prostate cancer by viral-based gene therapy.
Insights
Intraprostatic injection is the most effective route for delivering adenoviral gene therapy to the prostate in a canine model. This method shows higher gene transduction and expression compared to intravenous or intra-arterial delivery for prostate cancer treatment.
Area of Science:
- Oncology
- Gene Therapy
- Viral Vectors
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Gene therapy offers a novel approach to combat prostate cancer.
- Adenoviral vectors are being explored for targeted cancer treatment.
Purpose of the Study:
- To evaluate the efficacy of different delivery routes for adenoviral vectors in prostate gene therapy.
- To determine the optimal administration method for maximizing gene transduction in the prostate.
- To compare intraprostatic, intra-arterial, and intravenous delivery of adenoviral vectors.
Main Methods:
- A replication-deficient recombinant adenoviral vector (AdRSVlacZ) expressing beta-galactosidase (lacZ) was used.
- Adenoviral vectors were administered via intravenous, intra-arterial, and intraprostatic injections in a canine model.
- Gene expression was assessed using in situ staining, enzymatic assays, and PCR analysis.
Main Results:
- Intraprostatic (i.p.) injection resulted in significantly higher lacZ transduction rates and expression levels in the prostate compared to other routes.
- Adenoviral vector distribution and expression varied significantly based on the delivery method.
- Intraprostatic delivery demonstrated superior localized gene delivery to the prostate.
Conclusions:
- Intraprostatic injection is the most effective route for adenoviral vector-mediated gene therapy targeting the prostate.
- This finding supports the potential of intratumoral injection for treating localized prostate cancer.
- Optimizing delivery routes is crucial for the success of viral-based gene therapies.
